An atopic dermatitis patient list is not a study population, and a full appointment calendar is not evidence that a site can deliver dependable assessments. Sponsors selecting an eczema research site need to look at the work between diagnosis, baseline scoring, daily symptom reports and the final follow-up visit.
That work matters because atopic dermatitis changes over time. The National Institutes of Health describes a chronic inflammatory condition with flares, periods of improvement and often significant itch. A patient may have a documented diagnosis but not meet a protocol's current severity, prior-treatment or washout requirements. A realistic feasibility discussion therefore starts with the protocol, the investigator and the participant's routine, not a headline count.
Make the baseline assessment reproducible
Moderate-to-severe atopic dermatitis studies may use the Eczema Area and Severity Index (EASI), Investigator's Global Assessment (IGA), body surface area involvement and an itch scale. These instruments answer different questions. EASI characterizes the extent and severity of visible signs; IGA provides a clinician-rated global category; a patient-reported itch score captures an experience that may not track every visible skin finding.
FDA's clinical trial summaries for abrocitinib describe IGA and EASI-75 response endpoints, while the FDA's lebrikizumab summary describes IGA response and maintenance assessment over a longer treatment period. These are examples, not a universal scoring package. A new sponsor must specify the exact instruments, baseline thresholds, assessor rules and time points for its own study.
At feasibility, ask who will perform scoring, how training and calibration are documented, whether the same qualified assessor can cover key visits and what happens during an absence. Confirm what the protocol requires for photographs, lighting, privacy, anatomical-site consistency and assessment order. A site should not promise photography equipment, specialized imaging or certified assessors until its current location-specific capability is checked.
Look beyond the diagnosis and document treatment history
A medical record can establish prior eczema care without showing whether the participant has the specific disease burden required now. Prescreening needs a careful review of affected areas, current therapy, recent flares and, where permitted, the history of topical and systemic treatments. The investigator must apply the complete current protocol at formal screening.
This distinction is especially important as dermatology treatment options expand. Depending on the protocol, prior biologic exposure, oral targeted therapies, treatment response, topical background therapy and washout periods may substantially narrow the pool. The site should explain what it can verify from records, what needs a referring clinician's confirmation and what cannot be known until screening.
Ask how candidates reach the research team from dermatology and primary-care practices. An established referral relationship is more useful than a hypothetical referral pipeline. WCR's dermatology program describes specialty evaluation, patient relationships, bilingual contact and coordinated examinations, but each protocol still requires location-level feasibility.
Treat symptom diaries as a study operation
Itch and sleep disturbance can be important to participants, even when skin signs fluctuate. In the published JADE COMPARE trial, investigators evaluated clinician-rated skin endpoints as well as a Peak Pruritus Numerical Rating Scale. The presence of a daily or frequent symptom measure changes the site's work: participants must understand when and how to report, and the research team must identify missing entries early without suggesting what answer to give.
Ask to see the diary onboarding plan. Who confirms device or app access? Who explains recall periods and the difference between a missed entry and a symptom-free day? What is the escalation path for login problems or persistent missing data, and who documents contact attempts? If adolescents are eligible, how are the participant's own reports distinguished from caregiver assistance in accordance with the instrument and consent or assent requirements?
There should also be a rule for reviewing concerning symptoms without turning study diaries into an unmonitored safety channel. Sponsors and sites need a clear separation between research endpoints, participant questions and adverse-event reporting.
Plan the visit burden through the last assessment
A sponsor may focus on the first screening appointment, while a potential participant is deciding whether repeated clinic visits, investigational treatment, symptom reporting and possible laboratory checks fit into work, school or family life. In chronic skin disease, a participant may feel better during part of the trial or experience a flare. Neither situation removes the need for informed, voluntary follow-up under the protocol.
During feasibility, map every required visit, expected duration, procedure, rescheduling window and caregiver requirement. Then test the actual appointment capacity of the proposed location. Ask whether visits can be aligned with participant availability, what options exist for transportation when allowed, and how the team handles missed appointments or long intervals between assessments.
For studies that include adolescents, confirm appropriate pediatric experience, caregiver permissions, age-appropriate communication and school-hour constraints. The right response is not to promise universally flexible visits, but to show a staffing and escalation plan that is feasible for the protocol.
Use WCR experience with the correct boundaries
A published WCR phase 3 atopic dermatitis case study describes a demanding diary and visit schedule involving adults and adolescents. In that specific study, 30% of randomized participants were ages 12 to 17 and the reported participant completion was 100%. The team documented active diary monitoring, caregiver education, scheduling accommodations and transportation support.
Those results are evidence about that study, not a guarantee of equivalent performance for a new sponsor, disease population, endpoint or site. The more transferable lesson is operational: the team connected diary completeness with timely follow-up and planned for family availability instead of assuming enrolled participants would stay engaged on their own.
WCR also publicly identifies Dr. David A. Rodriguez as a dermatology and internal-medicine specialist with atopic dermatitis experience. Separately, PubMed lists Dr. Lucky Flores among the JADE COMPARE investigator collaborators, rather than as a main manuscript author. Sponsors should review those documented roles and ask which investigator would actually cover a proposed protocol at the proposed location.
A practical sponsor checklist before site selection
A useful feasibility answer identifies ownership and evidence rather than offering a single optimistic enrollment number. Before selection, request a short operational walkthrough covering the questions below. A site that can explain dependencies and limitations usually provides a more actionable starting point than one that only says it has eczema patients.
- Population: How were potential candidates identified, and which severity and treatment-history criteria can be checked before contact?
- Assessors: Who performs EASI, IGA and other required scales? What training, backup and visit consistency are available?
- Procedures: Which examinations, photography, sampling and laboratory steps are on site, and which depend on a verified partner?
- Diary support: Who trains participants, monitors missing entries and responds to technical problems without influencing answers?
- Visit capacity: Are the required windows, long visits and adolescent or caregiver schedules realistic for the location?
- Retention and safety: Who follows up missed visits, reviews symptoms and documents participant communication?
- Forecast: What is the defensible path from record review to contact, consent, screening and randomization, with uncertainty shown?
How to make a site decision that holds up during the study
For sponsors and CROs, the strongest atopic dermatitis site assessment joins three views: clinical eligibility, measurement quality and the practical demands of participation. Score the site's evidence for each separately. A highly experienced investigator cannot make up for a missing assessor backup, and a well-equipped exam room cannot substitute for a credible recruitment pathway.
Wellness Clinical Research coordinates a bilingual, multi-specialty network serving Miami Lakes and Vega Baja. The team can review proposed investigator responsibilities, patient access, study assessments, staffing, translation needs and visit support for each location. Suitability should always be confirmed against the actual protocol, not inferred from a therapeutic-area page or a historical outcome.
Sponsors and CROs can submit a study opportunity for a protocol-specific feasibility review. The discussion should leave both parties with a clear list of verified capabilities, unresolved dependencies and a realistic plan for participants through final follow-up.
